

Dr. Patrick Soon-Shiong to Deliver Keynote at HIMSS 2017 Intelligent Health™ Pavilion and Will Unveil NantDaVinci: the World's Largest Database of Analyzed Human Cancer Whole Genomes

February 13, 2017

NantHealth Founder and CEO to unveil publicly for the first time in 10 years, NantDaVinci, the world's first whole genomics transcriptomics supercomputing medical reasoning engine covered by over 100 seminal patents advancing immunotherapy as the next generation of cancer care and the potential for cancer vaccines

ORLANDO, Fla.--(BUSINESS WIRE)-- [NantHealth](#), Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today that Patrick Soon-Shiong, MD, has been chosen to keynote at the Intelligent Health™ Pavilion during the [HIMSS 2017 Annual Conference & Exhibition in Orlando, Florida](#). Dr. Soon-Shiong will introduce the NantDaVinci Cancer Engine, an augmented intelligence processor integrated into a secure terabit per second fiber network that rapidly analyzes genomes within a patient's cancer tumor. The keynote will take place on Monday, February 20, at 10:30 a.m. ET at booth 8361.

The presentation, “Unlocking the Code with the NantDaVinci Cancer Engine” will unveil how NantHealth has been leveraging advancements in supercomputing, augmented intelligence, machine vision, machine learning and natural language processing to identify and read the unique biological signature inside each cancer tumor and how that code can be unlocked to create a truly personalized treatment and a cancer vaccine.

To date, the NantDaVinci Supercomputing Engine has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with multiple tumor types—and with the world's largest database of human cancer whole genomes— has enabled the discovery of novel neoepitopes in cancer tissue for the development of neoepitope antibodies and vaccines in the war against cancer. Over 100 seminal patents have been issued covering this integrated augmented, amplified and adaptive intelligence platform.

The session will also be available for viewing via Facebook Live at www.Facebook.com/NantHealth.

WHAT: *Unlocking the Code with the NantDaVinci Cancer Engine*

WHO: Patrick Soon-Shiong, MD, founder and CEO, NantHealth

WHEN: Monday, February 20, 2017 at 10:30 a.m. - 11:30 a.m. EST

WHERE: HIMSS Annual Conference & Exhibition

Intelligent Health Pavilion, Booth 8361
Orange County Convention Center
Orlando, Florida

MEDIA

CONTACT: Jen Hodson

NantHealth

jhodson@nantworks.com

310-853-7802

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that may cause future results to differ materially from management's current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time

biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthhealth.com and follow Dr. Soon-Shiong on Twitter [@DrPatSoonShiong](https://twitter.com/DrPatSoonShiong).



View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170213005106/en/>

NantHealth
Jen Hodson, 310-853-7802
jhodson@nantworks.com

Source: NantHealth, Inc.